Table 2 Results of vaccine schedule impact on the prevalence of vaccine-type pneumococcal carriage in children aged 2–260 weeks with clinical pneumonia
Alternative schedule | Standard schedule | Adjusted prevalence ratio (95% CI) | |||||
|---|---|---|---|---|---|---|---|
Number VT Spn | Number measured | Prevalence % (95% CI) | Number VT Spn | Number measured | Prevalence (95% CI) | ||
Year 1 | n | N | n/N () | n | N | n/N () | x.y (95% CI) |
Year 2 | n | N | n/N () | n | N | n/N () | x.y (95% CI) |
Year 3 | n | N | n/N () | n | N | n/N () | x.y (95% CI) |
Year 4 | n | N | n/N () | n | N | n/N() | x.y (95% CI) |
aAge (weeks) | |||||||
2–12 | n | N | n/N () | n | N | n/N () | x.y (95% CI) |
13–40 | n | N | n/N () | n | N | n/N () | x.y (95% CI) |
41–104 | n | N | n/N () | n | N | n/N () | x.y (95% CI) |
105–260 | n | N | n/N () | n | N | n/N () | x.y (95% CI) |